臨床研究等提出・公開システム

A MULTICENTER, OPEN-LABEL PHASE 1 STUDY OF U3-1402 IN SUBJECTS WITH METASTATIC OR UNRESECTABLE NON-SMALL CELL LUNG CANCER

A PHASE 1 STUDY OF U3-1402 IN SUBJECTS NON-SMALL CELL LUNG CANCER

DAIICHI SANKYO Co.,Ltd.

1-2-58, Hiromachi, Shinagawa-ku, Tokyo

dsclinicaltrial@daiichisankyo.co.jp

DAIICHI SANKYO Co.,Ltd.

1-2-58, Hiromachi, Shinagawa-ku, Tokyo

+81-3-6225-1111

dsclinicaltrial@daiichisankyo.co.jp

recruiting

Nov. 20, 2019

Interventional

The primary objectives are: For Dose Escalation, to assess the safety and tolerability of HER3-DXd in the study population and to determine the recommended dose for expansion (RDE) of HER3-DXd in the study population For Dose Expansion, to investigate the antitumor activity of HER3-DXd For Cohort 5, investigate the antitumor activity of HER3-DXd in participants with locally advanced or metastatic NSCLC whose tumors harbor a KRAS-G12C mutation after the failure of targeted therapy The number of treatment cycles is not fixed in this study. Participants will continue study treatment (for approximately 36 months) until they decide not to (withdraw consent), their disease gets worse [progressive disease (PD)], or side effects become unacceptable (unacceptable toxicity) or other stopping reasons have been met.

treatment purpose

1

Inclusion Criteria for both Dose Escalation and Dose Expansion:
1. Has locally advanced or metastatic NSCLC, not amenable to curative surgery or radiation
2. Has at least one measurable lesion per RECIST version 1.1
3. Has Eastern Cooperative Oncology Group performance status of 0 or 1 at Screening

Inclusion Criteria for Dose Escalation only:
1. Has histologically or cytologically documented adenocarcinoma NSCLC
2. Has acquired resistance to EGFR TKI according to the Jackman criteria (PMID: 19949011)
a. Historical confirmation that the tumor harbors an epidermal growth factor receptor (EGFR) mutation known to be associated with EGFR tyrosine kinase inhibitor (TKI) sensitivity (including G719X, exon 19 deletion, L858R, L861Q)
b. Has experienced clinical benefit from an EGFR TKI, followed by systemic progression of disease [Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1] or World Health Organization (WHO)] while on continuous treatment with an EGFR TKI
3. Is currently receiving and able to discontinue erlotinib, gefinitib, afatinib, or osimertinib
4. Has been receiving erlotinib, gefitinib, afatinib, or osimertinib for at least 6 weeks with well-controlled related toxicities less than Grade 3 in severity at the time of Screening
5. Has radiological documentation of disease progression while receiving continuous treatment with erlotinib, gefitinib, afatinib, or osimertinib
6. Is willing to provide archival tumor tissue from a biopsy performed within 6 months of progression during treatment with erlotinib, gefitinib, afatinib, or osimertinib OR has at least one lesion, not previously irradiated, amenable to core biopsy and is willing to undergo screening tumor biopsy
7. Demonstrates absence of EGFR T790M mutation if treated with erlotinib, gefitinib, or afatinib. No EGFR mutation testing is required if treated with osimertinib.

Inclusion Criteria for all cohorts of Dose Expansion only:
1. Has received systemic therapy for locally advanced or metastatic disease including at least 1 platinum-based chemotherapy regimen
2. Has documented radiological disease progression during/after most recent treatment regimen for locally-advanced or metastatic disease
3. For Cohorts 1, 2, 3a, and 3b: Is willing to provide archival tumor tissue from a biopsy performed within 6 months of consent and performed after progression during/after treatment with most recent cancer therapy regimen OR has at least 1 lesion, not previously irradiated, amenable to core biopsy and is willing to undergo tumor biopsy. Tumor tissue must be of sufficient quantity as defined in the laboratory manual and contain adequate tumor tissue content as confirmed by haematoxylin and eosin (H&S) staining at central laboratory.
For Cohort 4: Neither archival tumor tissue nor core tumor biopsy will be collected

Inclusion Criteria specific to Cohorts 1, 3a, 3b, and 4 of Dose Expansion:
1. Has histologically or cytologically documented:
a. Cohort 1: Adenocarcinoma NSCLC
b. Cohorts 3a, 3b, and 4: NSCLC (including any histology other than small-cell or combined small cell and non-small cell)
2. Has documentation of radiological disease progression following one or more lines of EGFR TKI treatment. Participants with EGFR T790M mutation following treatment with erlotinib, gefitinib afatinib, or dacomitinib must have received and have documentation of radiological disease progression following treatment with osimertinib unless unable or unwilling.
3. Has documentation of EGFR-activating mutation(s) detected from tumor tissue: G719X, exon deletion 19, L858R, or L861Q. Participants with other EGFR-activating mutations may be eligible following discussion with the Sponsor.

Inclusion Criteria specific to Cohort 2 of Dose Expansion:
1. Has histologically or cytologically documented squamous or non-squamous NSCLC (ie, without EGFR-activating mutations).
2. Has received prior treatment with anti-PD-1 or anti-PD-L1 antibody-based regimen in the locally advanced or metastatic setting unless unable or unwilling. Participants with NSCLC known to harbor a genomic alteration(s) other than EGFR mutation(s) (eg, ALK or ROS1 fusion) for which treatment is available must have also received prior treatment with at least 1 genotype-directed therapy.

Inclusion Criteria for Cohort 5:

1. Sign and date the main study ICF, prior to the start of any study-specific qualification procedures. A separate tissue screening consent will be obtained from all participants.
2. Male or female subjects aged >=18 years (follow local regulatory requirements if the legal age of consent for study participation is >18 years old)
3. Has locally advanced or metastatic NSCLC not amenable to curative surgery or radiation.
4. Has histologically or cytologically documented squamous or nonsquamous NSCLC
5. Has documentation of KRAS-G12C mutation(s) detected from tumor tissue or liquid biopsy.
6. Has received at least two prior systemic therapies for locally advanced or metastatic disease, including one approved KRAS-G12C-targeted therapy (e.g., sotorasib or adagrasib, including as part of a clinical trial).
7. Has documentation of radiological disease progression according to RECIST v1.1 while either on or following the most recent treatment regimen for locally advanced or metastatic disease.
8. Has >=1 measurable lesion on computed tomography (CT) or magnetic resonance imaging (MRI) as per RECIST v1.1 by Investigator assessment that has not been previously irradiated.
9. Provides a pre-treatment tumor tissue sample of sufficient quantity, as defined in the laboratory manual.
10. ECOG PS 0 or 1 at the time of Screening.
11. Has adequate bone marrow reserve and organ function based on local laboratory data within 14 days prior to Cycle 1 Day 1 as specified in the protocol.
12. If the participant is a female of childbearing potential, she must have a negative serum pregnancy test at screening and must be willing to use a highly effective birth control upon enrollment, during the Treatment Period, and for 7 months following the last dose of study drug.
13. Female subjects must not donate, or retrieve for their own use, ova from the time of screening and throughout the study treatment period, and for at least 7 months after the time of final study drug administration.
14. If male, the subject must be surgically sterile or willing to use highly effective birth control upon enrollment, during the treatment period, and for at least 4 months following the last dose of study drug.
15. Male subjects must not freeze or donate sperm starting at screening and throughout the study period, and for at least 4 months after the final study drug administration.
16. Is willing and able to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restrictions.

Exclusion Criteria for Dose Escalation and Dose Expansion:
1. Has any evidence of small cell histology, or combined small cell and non-small cell histology, in original tumor biopsy or in Screening biopsy performed after progression
2. Treatment with any of the following:
a. Any cytotoxic chemotherapy, investigational agent or other anticancer drug(s) from a previous cancer treatment regimen or clinical study (other than EGFR TKI in Cohorts 1, 3a, 3b, and 4 only), within 14 days of the first dose of study treatment
b. Immune checkpoint inhibitor therapy within 21 days of the first dose of study treatment
c. Prior treatment with an anti-HER3 antibody (dose escalation only)
d. Prior treatment with a topoisomerase I inhibitor (dose escalation only)
e. Prior treatment with an antibody-drug conjugate (ADC) that consists of an exatecan derivative that is a topoisomerase I inhibitor (eg, DS-8201a) (dose escalation only)
f. Major surgery (excluding placement of vascular access) within 4 weeks of the first dose of study drug treatment
g. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug treatment, or palliative radiation therapy within 2 weeks of the first dose of study drug treatment, or stereotactic radiotherapy within 1 week prior to the first dose of HER3-DXd
3. Has history of other active malignancy within 3 years prior to enrollment, except:
a. Adequately treated non-melanoma skin cancer OR
b. Superficial bladder tumors (Ta, Tis, T1) OR
c. Curatively treated in situ disease
4. Has spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms. Participants with clinically inactive brain metastases may be included in the study. Participants with treated brain metastases that are no longer symptomatic and who require no treatment with corticosteroids or anticonvulsants may be included in the study if they have recovered from the acute toxic effect of radiotherapy. A minimum of 2 weeks must have elapsed between the end of whole brain radiotherapy and study enrollment (1 week for stereotactic radiotherapy)
5. Has history of myocardial infarction within the past 6 months
6. Has symptomatic congestive heart failure[New York Heart Association (NYHA) Classes II-IV], unstable angina within the past 6 months, or cardiac arrhythmia requiring antiarrhythmic treatment
7. Has left ventricular ejection fraction (LVEF) < 50% by either echocardiogram (ECHO) or multigated acquisition scan (MUGA)
8. Has any clinically important abnormalities in rhythm, conduction or morphology of resting electrocardiogram (ECG), eg, complete left bundle branch block, third-degree heart block, second-degree heart block, or PR interval > 250 milliseconds (ms)
9. Has a mean corrected QT interval using Fridericia's Correction Formula (QTcF) prolongation to > 470 ms for females and > 450 ms for males in three successive Screening measurements
10. Unable or unwilling to discontinue concomitant drugs that are known to prolong the QT interval
11. Has any factors that increase the risk of corrected QT (QTc) interval prolongation or risk of arrhythmic events, such as congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives.
12. Has any history of interstitial lung disease (ILD) (including pulmonary fibrosis or severe radiation pneumonitis), has current ILD/pneumonitis, or is suspected to have such disease by imaging during screening
13. Has clinically significant corneal disease

Additional Exclusion Criteria for Dose Expansion Cohort 2:
1. Has documentation of one or more of the following EGFR-activating mutations: G719X, exon 19 deletion, L858R, or L861Q

Additional Exclusion Criteria for Dose Expansion Cohort 4:
1. Evidence of any leptomeningeal disease
2. Clinically severe respiratory compromise (based on Investigator's assessment) resulting from intercurrent pulmonary illnesses including, but not limited to:
a. Any underlying pulmonary disorder
b. Any autoimmune, connective tissue or inflammatory disorders with pulmonary involvement OR prior complete pneumonectomy
3. Is receiving chronic systemic corticosteroids dosed at >10 mg/day prednisone or equivalent anti-inflammatory activity or any form of immunosuppressive therapy prior to enrollment
4. Resting systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg
5. Prior or ongoing clinically relevant illness, medical condition, surgical history, physical finding, or laboratory abnormality that could affect the safety of the subject; alter the absorption, distribution, metabolism or excretion of the study drug; or confound the assessment of study results.

Exclusion Criteria for Cohort 5:
1. Has any evidence of small-cell histology or combined small cell and non-small-cell histology in the original tumor tissue or in Screening biopsy performed after progression.
2. Has received a targeted therapy for an actionable genomic alteration other than KRAS-G12C.
3. Any history of interstitial lung disease (ILD) (including pulmonary fibrosis or radiation pneumonitis) has current ILD, or is suspected to have such disease by imaging during screening.
4. Has clinically severe respiratory compromise (based on the Investigator's assessment) resulting from intercurrent pulmonary illnesses.
5. Is receiving chronic systemic corticosteroids dosed at >10 mg/day prednisone or equivalent anti-inflammatory activity or any form of immunosuppressive therapy prior to Cycle 1 Day 1.
6. Has any history of or evidence of current leptomeningeal disease.
7. Has clinically significant corneal disease.
8. Evidence of spinal cord compression or brain metastases, defined as being symptomatic and untreated, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms.
9. Inadequate washout period prior to Cycle 1 Day 1 as specified in the protocol.
10. Prior treatment with an anti-HER3 antibody and/or antibody drug conjugate (ADC) that consists of an exatecan derivative that is a topoisomerase I inhibitor (eg, trastuzumab deruxtecan).
11. Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to National Cancer Institute- Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0), Grade <=1 or baseline.
12. Has known hypersensitivity to either the drug substance or inactive ingredients in the drug product.
13. Has history of other active malignancy within 3 years prior to Cycle 1 Day 1, with exceptions as specified in the protocol.
14. Uncontrolled or significant cardiovascular disorder prior to Cycle 1 Day 1,
15. Active Hepatitis B and/or Hepatitis C infection, such as that with serologic evidence of active viral infection within 28 days of randomization.
16. Participants with past or resolved Hepatitis B virus (HBV) infection are eligible if meeting certain criteria as specified in the protocol.
17. Participants with a history of Hepatitis C infection will be eligible for enrollment only if the viral load according to local standards of detection is documented to be below the level of detection in the absence of anti-viral therapy during the previous 12 weeks.
18. Is a female participant who is pregnant or breastfeeding or intends to become pregnant during the study.
19. Has a known HIV infection that is not well controlled.
20. In the Investigator's opinion, it is deemed high risk for the subject to participate in the study as specified in the protocol.

Both

Non-small Cell Lung Cancer

investigational material(s)
Generic name etc : HER3-DXd
INN of investigational material : -
Therapeutic category code : 429 Other antitumor agents
Dosage and Administration for Investigational material : intravenous

control material(s)
Generic name etc : -
INN of investigational material : -
Therapeutic category code :
Dosage and Administration for Investigational material : -

safety
efficacy
1. Dose-limiting toxicities (DLTs) during dose escalation [Time Frame: 21 days of Cycle 1]
2. Summary of adverse events during dose escalation [Time Frame: By the global end of trial date, approximately within 36 months]
3. Overall response rate (ORR) assessed by Blinded Independent Central Review (BICR) Committee during dose expansion (Cohorts 1, 2, 3a, 3b, and 5) [Time Frame: Approximately within 36 months]
ORR will be evaluated using RECIST v1.1.
4. Maximum serum concentration (Cmax) of HER3-DXd, total anti-HER3 antibody, and MAAA-1181a during dose expansion (Cohort 4) [Time Frame: During the first 5 cycles (each cycle is 21 days), including an intensive sampling schedule: pre-dose, end of infusion (EOI), 2 hour (hr), 4 hr, 8 hr post infusion, Day 8, and Day 15.]
5. Area under the serum concentration-time curve from time 0 extrapolated to infinity (AUCinf) and up to last quantifiable time (AUC[last]) of HER3-DXd, total anti-HER3 antibody, and MAAA-1181a during dose expansion (Cohort 4) [Time Frame: During the first 5 cycles (each cycle is 21 days), including an intensive sampling schedule: pre-dose, end of infusion (EOI), 2 hour (hr), 4 hr, 8 hr post infusion, Day 8, and Day 15.]

safety
efficacy
exploratory
pharmacokinetics
pharmacodynamics
pharmacogenomics
patient-reported outcomes
1. Maximum serum concentration (Cmax) of HER3-DXd, total anti-HER3 antibody, and MAAA-1181a during dose escalation [Time Frame: During the first 5 cycles (each cycle is 21 days), including an intensive sampling schedule: pre-dose, end of infusion (EOI), 2 hour (hr), 4 hr, 8 hr post infusion, Day 8, and Day 15.]
2. Time of maximum concentration (Tmax) of HER3-DXd, total anti-HER3 antibody, and MAAA-1181a during dose escalation [Time Frame: During the first 5 cycles (each cycle is 21 days), including an intensive sampling schedule: pre-dose, end of infusion (EOI), 2 hour (hr), 4 hr, 8 hr post infusion, Day 8, and Day 15.]
3. Area under the serum concentration-time curve from time 0 to 21 days (AUC[0-21d]) and up to last quantifiable time (AUC[last]) of HER3-DXd, total anti-HER3 antibody, and MAAA-1181a during dose escalation [Time Frame: During the first 5 cycles (each cycle is 21 days), including an intensive sampling schedule: pre-dose, end of infusion (EOI), 2 hour (hr), 4 hr, 8 hr post infusion, Day 8, and Day 15.]
4. Overall response rate (ORR) during dose escalation [Time Frame: Approximately within 36 months]
Evaluated using RECIST 1.1
5. Disease control rate (DCR) during dose escalation [Time Frame: Approximately within 36 months]
6. Duration of response (DOR) during dose escalation [Time Frame: Approximately within 36 months]
7. Time to response (TTR) during dose escalation [Time Frame: Approximately within 36 months]
8. Progression free survival (PFS) during dose escalation [Time Frame: Approximately within 36 months]
9. Overall Survival (OS) during dose escalation [Time Frame: Approximately within 36 months]
10. Summary of adverse events during dose expansion (Cohorts 1-5) [Time Frame: By the global end of trial date, approximately within 60 months]
11. Maximum serum concentration (Cmax) of HER3-DXd, total anti-HER3 antibody, and MAAA-1181a during dose expansion (Cohorts 1-3, 5) [Time Frame: During the first 5 cycles (each cycle is 21 days), including an intensive sampling schedule: pre-dose, end of infusion (EOI), 2 hour (hr), 4 hr, 8 hr post infusion, Day 8, and Day 15.]
12. Time of maximum concentration (Tmax) of HER3-DXd, total anti-HER3 antibody, and MAAA-1181a during dose expansion (Cohorts 1-5) [Time Frame: During the first 5 cycles (each cycle is 21 days), including an intensive sampling schedule: pre-dose, end of infusion (EOI), 2 hour (hr), 4 hr, 8 hr post infusion, Day 8, and Day 15.]
13. Area under the serum concentration-time curve from time 0 to Day 21 (AUC[0-21d]), and up to last quantifiable time (AUC[last]) of HER3-DXd, total anti-HER3 antibody, and MAAA-1181a during dose expansion (Cohorts 1-3, 5) [Time Frame: During the first 5 cycles (each cycle is 21 days), including an intensive sampling schedule: pre-dose, end of infusion (EOI), 2 hour (hr), 4 hr, 8 hr post infusion, Day 8, and Day 15.]
14. Overall response rate (ORR) by Investigator during dose expansion (Cohorts 1-5)
[Time Frame: Approximately within 60 months ]Evaluated using RECIST 1.1
15. Disease control rate (DCR) during dose expansion (Cohorts 1-5) [Time Frame: Approximately within 60 months]
16. Duration of response (DOR) during dose expansion (Cohorts 1-5) [Time Frame: Approximately within 60 months]
17. Time to response (TTR) during dose expansion (Cohorts 1-5) [Time Frame: Approximately within 60 months]
18. Progression free survival (PFS) during dose expansion (Cohorts 1-5) [Time Frame: Approximately within 60 months]
19. Overall survival (OS) during dose expansion (Cohorts 1-5) [Time Frame: Approximately within 60 months]
20. Percentage of participants who are anti-drug antibody (ADA)-positive (baseline and post-baseline) and Percentage of participants who have treatment-emergent ADA during dose expansion (Cohort 4) [Time Frame: Approximately within 60 months]
21. Mean Change from Baseline in the NSCLC-SAQ Total Score (Cohort 5) [Time Frame: Approximately within 60 months]
The NSCLC-SAQ will assess symptom severity over the previous 7 days. Participants will respond using a 5-point verbal rating scale ranging from 0 "No (symptom) at all" to 4 "Very severe (symptom)" or from 0 "Never" to 4 "Always". NSCLC-SAQ total score is the sum of 5 domains (cough, pain, dyspnea, fatigue, and poor appetite) and ranges between 0 and 20. Higher scores indicate more severe symptomatology. Mean change from baseline in NSCLC-SAQ total score will be reported.
22. Percentage of Patients With Deteriorated, Stable, or Improved Symptoms from NSCLC-SAQ (Cohort 5) [Time Frame: Approximately within 60 months]
23. Percentage of Patients With Deteriorated, Stable, or Improved Symptoms from PRO-CTCAE (Cohort 5) [Time Frame: Approximately within 60 months]

+81-72-366-0221

Oct. 21, 2019